Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:26:43 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:OCUL - OCULAR THERAPEUTIX INC - http://www.ocutx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OCUL - Q0.15.38·6.050.15.87+0.8516.93,479.518,65615,0905.06  5.95  4.9311.31  1.99519:43:00May 0115 min RT 2¢

Recent Trades - Last 10 of 15090
Time ETExPriceChangeVolume
19:43:00Q6.000.981,085
19:37:35Q6.021.005
19:35:50Q5.960.9434
19:17:44Q6.041.022
18:48:00Q5.880.8610
18:31:19Q5.880.861
17:59:18Q6.041.0220
17:22:11Q6.03881.018899
17:21:59Q6.041.025
17:11:14Q5.990.97250

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-01 07:30U:OCULNews ReleaseOcular Therapeutix(TM) to Host Investor Day in New York City on Thursday, June 13, 2024
2024-04-18 07:00U:OCULNews ReleaseOcular Therapeutix(TM) Announces Positive Topline Phase 1 Data for AXPAXLI(TM) in Diabetic Retinopathy
2024-04-16 07:00U:OCULNews ReleaseOcular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders
2024-04-15 07:00U:OCULNews ReleaseOcular Therapeutix(TM) Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
2024-04-09 07:30U:OCULNews ReleaseOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
2024-04-06 10:00U:OCULNews ReleaseOcular Therapeutix(TM) Announces Positive Phase 2 PAXTRAVA(TM) Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
2024-03-26 07:30U:OCULNews ReleaseOcular Therapeutix(TM) To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
2024-03-11 16:05U:OCULNews ReleaseOcular Therapeutix(TM) Reports Fourth Quarter and Full Year 2023 Results
2024-03-05 07:30U:OCULNews ReleaseOcular Therapeutix(TM) to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
2024-02-22 07:32U:OCULNews ReleaseOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
2024-02-22 07:31U:OCULNews ReleaseOcular Therapeutix, Inc. Announces $325.0 Million Private Placement
2024-02-22 07:30U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Board of Directors and Leadership Updates
2024-02-19 09:00U:OCULNews ReleaseAffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA ‚ ® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiv
2024-02-15 08:00U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Appoints Steve Meyers to Chief Commercial Officer
2024-02-13 07:38U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI ¢ „ ¢ in Wet AMD
2024-01-25 08:00U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI ¢ „ ¢ in Wet AMD
2023-12-18 16:01U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2023-12-13 22:10U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Pricing of Public Offering of Common Stock
2023-12-13 16:01U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Proposed Public Offering of Common Stock
2023-11-08 08:00U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ to Present at Three Upcoming Investor Conferences